Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants.
The company reported results from four ad
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, Feb. 24, 2026, at 3:30 p.m. ET, featuring Kevin M. Flanigan, MD, the Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and professor of pediatrics and neurology at The Ohio State University College of Medicine. Dr. Flanigan will join company management to discuss the unmet need and current treatment landscape for Duchenne muscular dystrophy (DMD). Interested participants may register here.
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will present at and participate in the following investor conferences:
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in NYC on Thursday, Feb. 12, 2026, at 10 a.m. ET.
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has completed its previously-announced underwritten public offering (the “Offering”) of 5,168,019 common shares, which includes the exercise of the underwriters’ option to purchase an additional 712,574 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares were sold at a price of US$10.10 per share (C$13.81 per common share) and the pre-funded warrants were sold at a price of US$10.09999 per pre-funded warrant (C$13.80999 per pre-funded warrant), which represents the per share price for the common shares less the C$0.00001 per share exercise price for each pre-funded warrant. The total gross proceeds to the Company were approximately US$57.2 million, before deducting the underwriting discounts and commissions.
